Ken Griffin’s CalciMedica CALC Stock Holding History

Ken Griffin’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,686	Closed	-$50.3K	–	12946
2022 Q1	$63K	Sell	3,686 -548	-13%	-$10.4K	﹤0.01%	12646
2021 Q4	$108K	Sell	4,234 -1,592	-27%	-$61.8K	﹤0.01%	12637
2021 Q3	$271K	Buy	+5,826	New	+$328K	﹤0.01%	11277
2020 Q4	–	Sell	-27,878	Closed	-$4.96M	–	10935
2020 Q3	$4.96M	Buy	+27,878	New	+$5.81M	﹤0.01%	3166

Other funds holding CALC

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

SFFS

Stonehage Fleming Financial Services St. Helier, Jersey $2.75B AUM 13.81% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ken Griffin's CALC Position: Q2 2022 in Review

Ken Griffin sold out of CalciMedica (CALC) in Q2 2022, closing a stake of 3,686 shares — an estimated $50.3K sold.

Ken Griffin first reported a position in CALC in Q3 2020 and held it in 4 quarters. The position peaked at $4.96M in Q3 2020. 25 funds tracked by Wall St. Rank hold CALC as of Q2 2022.

Ken Griffin reported no remaining CalciMedica position as of Q2 2022 after selling out during the quarter.
Ken Griffin sold 3,686 CalciMedica shares in Q2 2022, an estimated $50.3K.
Ken Griffin first reported a position in CalciMedica in Q3 2020 and held it in 4 quarters.
Ken Griffin's CalciMedica position peaked at $4.96M in Q3 2020.
25 funds tracked by Wall St. Rank held CalciMedica as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.